HAB HIV Performance Measures: 

ADAP: AIDS Drug Assistance Program 

Performance Measure: ADAP: Formulary 

Percentage of new anti-retroviral classes that are included in the ADAP formulary within 90 days of the date 

of inclusion of new anti-retroviral classes in the PHS Guidelines for the Use of Antiretroviral Agents in HIV1-infected Adults and Adolescents1

 during the measurement year. 

Numerator 

Number of new anti-retroviral classes included into the ADAP formulary within 90 

days of the publication of updated PHS Guidelines for the Use of Antiretroviral Agents 

in HIV-1-infected Adults and Adolescents that include new anti-retroviral drug class 

during the measurement year. 

Denominator: Total number of new antiretroviral classes published in updated PHS Guidelines during 

the measurement year. 

Exclusions: 1. PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and 

Adolescents published in the last 90 days of the measurement year. 

Data Element: 

1. Did the updated PHS Guidelines for the Use of Antiretroviral Agents in HIV-1­

infected Adults and Adolescents include any new anti-retroviral classes? (Y/N) 

a. If yes, (for each new class) was the new class included into the ADAP 

formulary within 90 days of publication of updated PHS Guidelines for the Use 

of Antiretroviral Agents in HIV-1-infected Adults and Adolescents? (Y/N) 

i. If yes, list the date of publication of PHS Guidelines for the Use of 

Antiretroviral Agents in HIV-1-infected Adults and Adolescents and date of 

inclusion in the ADAP formulary. 

Data Sources: 

 AIDS Drug Assistance Program Quarterly Data Report 

 PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and 

Adolescents 

National Goals, 

Targets, or 

Benchmarks for 

Comparison: 

None available at this time. 

Basis for Selection: 

The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415)2 mandates that the state-operated 

ADAP programs “shall ensure that the therapeutics included on the list of classes of core antiretroviral 

therapeutics established by the Secretary under subsection (e) are, at a minimum, the treatments provided by 

the State pursuant to this section”. All ADAPs must include agents from each of the core antiretroviral 

classes listed in PHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and 

Adolescents3, 4

. These legislative and policy requirements have also been specified in the Part B ADAP 

Grant Application5 

. 

US Public Health Service Guidelines: 

US Public Health Service Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and 

ADAP Final |December 10, 2009 | Page 5 of 9 
HAB HIV Performance Measures: 

ADAP: AIDS Drug Assistance Program 

Performance Measure: ADAP: Formulary 

Adolescents1 contains the list of classes of core antiretroviral therapeutics to be included in ADAP 

formularies. 

References/Notes: 

1

 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral 

agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 

2009; 1-161.. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 

December 7, 2009. 

2

 The Ryan White HIV Treatment Modernization Act of 2006 (P.L. 109-415), Section 202(a). 

3

 HRSA/HAB, Policy Notice-07-03, “The Use of Ryan White HIV/AIDS Program, Part B (formerly Title II), AIDS 

Drug Assistance Program (ADAP) Funds for Access, Adherence and Monitoring Services”, September 2007 

4

 Deborah Parham Hopson, Ph.D., R.N., Assistant Surgeon General, Associate Administrator, HIV/AIDS Bureau, 

HRSA letter to Part B Grantees, February 1, 2008. 

5 HRSA/HAB Division of Service Systems Program Guidance: HIV Care Grant Program Part B: States/Territories 

Formula and Supplemental Awards and AIDS Drug Assistance Program Formula and Supplemental Awards, HRSA 

Announcement Numbers: HRSA 09-182 and 09-183. 

ADAP Final |December 10, 2009 | Page 6 of 9